Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Open in Screener

CRDF

Cardiff Oncology Inc

Jan 17 • 04:00PM ET

3.45

Dollar change +0.05
Percentage change 1.47	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC FOLD XNCR NERV AFMD ONC KPTI CARA ATNM

| Held by: VTI IWM VXF VTWO IWN IWO IWC AVSC RSSL VTWV

Index	RUT	P/E	-	EPS (ttm)	-0.95	Insider Own	6.00%	Shs Outstand	66.52M	Perf Week	-4.43%
Market Cap	229.49M	Forward P/E	-	EPS next Y	-0.98	Insider Trans	10.50%	Shs Float	62.53M	Perf Month	-14.39%
Income	-43.01M	PEG	-	EPS next Q	-0.25	Inst Own	27.02%	Short Float	15.20%	Perf Quarter	23.66%
Sales	0.69M	P/S	332.59	EPS this Y	-6.21%	Inst Trans	54.98%	Short Ratio	4.51	Perf Half Y	46.19%
Book/sh	1.01	P/B	3.40	EPS next Y	0.95%	ROA	-56.80%	Short Interest	9.51M	Perf Year	134.69%
Cash/sh	0.87	P/C	3.98	EPS next 5Y	-	ROE	-67.57%	52W Range	1.44 - 6.42	Perf YTD	-20.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.42%	ROI	-85.38%	52W High	-46.26%	Beta	1.78
Dividend TTM	-	Quick Ratio	4.74	Sales past 5Y	20.41%	Gross Margin	40.35%	52W Low	139.58%	ATR (14)	0.37
Dividend Ex-Date	-	Current Ratio	4.74	EPS Y/Y TTM	-3.88%	Oper. Margin	-6735.99%	RSI (14)	45.05	Volatility	5.91% 10.84%
Employees	32	Debt/Eq	0.03	Sales Y/Y TTM	49.78%	Profit Margin	-6241.65%	Recom	1.00	Target Price	11.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-16.15%	Payout	-	Rel Volume	0.61	Prev Close	3.40
Sales Surprise	135.71%	EPS Surprise	7.24%	Sales Q/Q	17.02%	Earnings	Nov 07 AMC	Avg Volume	2.11M	Price	3.45
SMA20	-14.46%	SMA50	0.37%	SMA200	11.34%	Trades		Volume	1,279,991	Change	1.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-06-24	Initiated	Craig Hallum	Buy	$8
Jan-05-22	Initiated	William Blair	Outperform
Dec-08-21	Initiated	Robert W. Baird	Outperform	$19
Aug-09-21	Resumed	Maxim Group	Buy	$30 → $20
Oct-22-20	Initiated	H.C. Wainwright	Buy	$27
Oct-08-20	Initiated	Piper Sandler	Overweight	$25

Dec-26-24 09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire) +10.71%
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -5.12%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire) -16.07%
Dec-14-24 06:50AM	Cardiff Oncology price target raised to $10 from $7 at Piper Sandler (TipRanks)
Dec-11-24 07:19AM	Cardiff Oncology Reports Promising Phase 2 Trial Results (TipRanks)
07:20AM	Loading…
Dec-10-24 07:20AM	Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering (GlobeNewswire) +54.92%
06:00AM	Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial (GlobeNewswire)
Nov-19-24 08:00AM	Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC (GlobeNewswire)
Nov-07-24 04:05PM	Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update (GlobeNewswire) +7.35% -24.69%
Oct-30-24 04:30PM	Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC (GlobeNewswire)
Aug-08-24 04:05PM	Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update (GlobeNewswire) +11.74%
Aug-01-24 04:05PM	Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update (GlobeNewswire)
May-29-24 04:05PM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-13-24 04:05PM	Cardiff Oncology to Present at Upcoming Investor Conferences in May (GlobeNewswire)
May-09-24 12:15PM	Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036 (PR Newswire) +5.62%
06:00AM	Loading…
May-07-24 06:00AM	The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 (InvestorPlace)
May-02-24 09:54PM	CRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.91% -21.43%
05:45PM	Cardiff Oncology (CRDF) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update (GlobeNewswire)
Apr-25-24 04:05PM	Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update (GlobeNewswire)
Apr-08-24 04:05PM	Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study (GlobeNewswire)
Apr-01-24 08:50AM	Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) +7.30%
Mar-21-24 07:55AM	Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why (Zacks)
Mar-14-24 08:50AM	Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going (Zacks)
08:08AM	Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? (Zacks)
Mar-06-24 04:05PM	Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024 (GlobeNewswire) +6.58% -9.77%
12:00PM	What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-01-24 10:12AM	Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +64.87%
Feb-29-24 07:40PM	Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:07PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (GlobeNewswire)
04:06PM	Loading…
04:06PM	Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC (GlobeNewswire)
04:05PM	Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) (GlobeNewswire)
Feb-26-24 08:00AM	Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 08:00AM	Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update (GlobeNewswire)
Jan-17-24 10:30AM	Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research (PR Newswire) -9.82%
Nov-20-23 04:05PM	Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference (PR Newswire)
Nov-02-23 04:05PM	Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire) +8.57%
Oct-26-23 04:05PM	Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire) -10.27%
Oct-11-23 09:35AM	Cardiff Oncology (CRDF) Loses -29.75% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-26-23 04:05PM	Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy (PR Newswire)
Sep-05-23 08:00AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Aug-09-23 04:05PM	Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire) -12.39% +8.38%
Aug-07-23 04:05PM	Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship (PR Newswire) -8.19% +38.85%
Jul-24-23 05:09PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 05:22PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-05-23 08:00AM	Cardiff Oncology to Present at the Jefferies Healthcare Conference (PR Newswire)
May-04-23 04:10PM	Cardiff Oncology Reports First-Quarter 2023 Results and Provides Business Update (PR Newswire)
Mar-28-23 08:00AM	Cardiff Oncology Announces First Patient Dosed in ONSEMBLE Phase 2 Randomized Trial of Onvansertib in Patients with Metastatic Colorectal Cancer (PR Newswire)
Mar-06-23 08:15AM	Cardiff Oncology Formally Introduces Scientific Advisory Board (PR Newswire)
Mar-04-23 07:11AM	Cardiff Oncology Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Mar-02-23 04:10PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
Feb-27-23 08:15AM	Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference (PR Newswire)
Feb-02-23 08:00AM	Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer (PR Newswire)
Jan-10-23 08:00AM	Cardiff Oncology to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 10:52AM	Cardiff Oncology to Present at Upcoming Investor Conferences (PR Newswire)
Nov-08-22 08:15AM	Cardiff Oncology to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-03-22 04:10PM	Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates (PR Newswire)
Sep-12-22 04:05PM	Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates (PR Newswire) +10.69% -41.12%
Sep-10-22 07:30AM	Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 (PR Newswire)
Sep-08-22 08:15AM	Cardiff Oncology to Present at Upcoming Investor Conferences in September (PR Newswire)
Sep-06-22 08:00AM	Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 (PR Newswire) -9.25%
Aug-29-22 08:00AM	Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 (PR Newswire) -5.73%
Aug-04-22 04:10PM	Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates (PR Newswire) +10.00%
Jul-05-22 08:30AM	Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire) +13.73%
Jul-02-22 09:10AM	Is Cardiff Oncology, Inc. (NASDAQ:CRDF) Popular Amongst Institutions? (Simply Wall St.)
May-17-22 08:30AM	Cardiff Oncology to Present at the H.C. Wainwright Global Investment Conference (PR Newswire) +6.06%
May-09-22 08:02AM	Here's Why We're Not Too Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation (Simply Wall St.) -6.06%
May-05-22 04:10PM	Cardiff Oncology Reports First Quarter 2022 Results and Provides Business Updates (PR Newswire) -6.29%
Apr-12-22 04:00PM	Cardiff Oncology Announces Departure of Chief Medical Officer (PR Newswire)
Apr-08-22 01:05PM	Cardiff Oncology Announces Updated Clinical and New Biomarker Data from Phase 2 Metastatic Castration-Resistant Prostate Cancer Trial at the AACR Annual Meeting (PR Newswire)
01:05PM	Cardiff Oncology Announces Data Showing the Combination of PARP Inhibition with Onvansertib Overcomes PARP Inhibitor Resistance in BRCA1-mutant and Wildtype Patient-Derived Xenograft Ovarian Cancer Models (PR Newswire)
Mar-22-22 09:05AM	Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC (PR Newswire) +7.56%
Mar-17-22 06:32AM	Cardiff Oncology, Inc. (NASDAQ:CRDF) insiders placed bullish bets worth US$681k in the last 12 months (Simply Wall St.) +6.48%
Mar-08-22 04:45PM	Cardiff Oncology Announces Upcoming Poster Presentations at the AACR Annual Meeting (PR Newswire) +7.76%
Mar-01-22 08:30AM	Cardiff Oncology to Participate in Cowen's 42nd Annual Healthcare Conference (PR Newswire)
Feb-24-22 04:10PM	Cardiff Oncology Reports Fourth Quarter and Full Year 2021 Results and Recent Highlights (PR Newswire) +7.49%
Feb-17-22 03:02PM	Cardiff Oncology (CRDF) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks) -5.79%
Jan-31-22 06:22PM	Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.96%
Jan-20-22 03:44PM	Dont Say Bye Bye to Cardiff Stock, Say Buy Buy: Analyst (TipRanks) -14.95%
01:46PM	Cardiff Oncology to Present at the B. Riley Securities 2022 Oncology Conference (PR Newswire)
Jan-18-22 05:00PM	Cardiff Oncology Announces New Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival (PR Newswire) -10.50% -25.90%
Jan-13-22 09:17AM	Are Institutions Heavily Invested In Cardiff Oncology, Inc.'s (NASDAQ:CRDF) Shares? (Simply Wall St.)
Jan-11-22 08:00AM	Cardiff Oncology Appoints Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, RPh, as Senior Vice President, Regulatory Affairs (PR Newswire) +10.18%
Jan-10-22 08:00AM	Cardiff Oncology to Host Conference Call and Webcast to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer Being Presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (PR Newswire)
Jan-04-22 08:00AM	Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference (PR Newswire)
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-10-21 08:30AM	Cardiff Oncology Announces Upcoming Presentation on Lead KRAS-mutated Metastatic Colorectal Cancer Program at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (PR Newswire)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com) +11.07%
Dec-03-21 08:30AM	Cardiff Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-18-21 07:00AM	Cardiff Oncology Announces $15 Million Equity Investment from Pfizer through its Pfizer Breakthrough Growth Initiative (PR Newswire) +18.74%
Nov-14-21 07:18AM	Cardiff Oncology (NASDAQ:CRDF) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-09-21 08:30AM	Cardiff Oncology to Present at Upcoming Jefferies London Healthcare and Piper Sandler 33rd Annual Investor Conferences (PR Newswire)
Nov-04-21 04:15PM	Cardiff Oncology Reports Third Quarter 2021 Results and Provides Business Updates (PR Newswire)
Oct-28-21 03:06PM	Will Cardiff Oncology (CRDF) Report Negative Q3 Earnings? What You Should Know (Zacks)
Sep-30-21 08:36PM	Insider Buying Could Indicate a Bottom in These 2 Stocks (TipRanks) +8.71%
Sep-15-21 06:37AM	James Levine Is The Chief Financial Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF) And Just Spent US$194k On Shares (Simply Wall St.)
Sep-08-21 04:00PM	Cardiff Oncology Announces New Data from Phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer Showing Robust Objective Response Rate and Progression Free Survival (PR Newswire)

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Levine James E.	Chief Financial Officer	Dec 17 '24	Buy	5.42	2,752	14,905	65,316	Dec 18 04:37 PM
Levine James E.	Chief Financial Officer	Dec 18 '24	Buy	5.00	2,400	12,000	67,716	Dec 18 04:37 PM
Levine James E.	Chief Financial Officer	Dec 16 '24	Buy	3.83	2,564	9,820	62,564	Dec 18 04:37 PM
TANNENBAUM RENEE P	Director	Dec 12 '24	Buy	3.42	10,000	34,224	20,000	Dec 16 05:00 PM
PACE GARY W	Director	Dec 11 '24	Buy	2.60	350,115	910,299	1,047,876	Dec 12 04:05 PM
PACE GARY W	Director	Dec 11 '24	Buy	2.60	11,500	29,900	1,059,376	Dec 12 04:05 PM

Dollar change +0.96
Percentage change 1.67	%

ANIP ANI Pharmaceuticals Inc daily Stock Chart

Peers: AMGN REGN VRTX BIIB GILD ILMN BMRN INCY NBIX UTHR

| Held by: IJR VTI IWM VXF SPSM IJT PJP IWO SLYG VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.54	Insider Own	17.17%	Shs Outstand	21.07M	Perf Week	6.21%
Market Cap	1.23B	Forward P/E	10.52	EPS next Y	5.56	Insider Trans	-1.44%	Shs Float	17.42M	Perf Month	3.73%
Income	-10.52M	PEG	-	EPS next Q	1.44	Inst Own	92.10%	Short Float	12.33%	Perf Quarter	-2.01%
Sales	555.46M	P/S	2.21	EPS this Y	6.30%	Inst Trans	27.29%	Short Ratio	8.22	Perf Half Y	-4.71%
Book/sh	19.26	P/B	3.04	EPS next Y	11.02%	ROA	-0.82%	Short Interest	2.15M	Perf Year	5.14%
Cash/sh	7.29	P/C	8.02	EPS next 5Y	-	ROE	-2.13%	52W Range	52.50 - 70.81	Perf YTD	5.75%
Dividend Est.	-	P/FCF	16.15	EPS past 5Y	-6.27%	ROI	-1.00%	52W High	-17.44%	Beta	0.74
Dividend TTM	-	Quick Ratio	1.96	Sales past 5Y	26.21%	Gross Margin	48.93%	52W Low	11.35%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	2.74	EPS Y/Y TTM	-186.25%	Oper. Margin	1.73%	RSI (14)	62.05	Volatility	3.12% 3.09%
Employees	642	Debt/Eq	1.60	Sales Y/Y TTM	23.60%	Profit Margin	-1.89%	Recom	1.50	Target Price	78.67
Option/Short	Yes / Yes	LT Debt/Eq	1.58	EPS Q/Q	-354.02%	Payout	0.00%	Rel Volume	1.16	Prev Close	57.50
Sales Surprise	2.74%	EPS Surprise	23.39%	Sales Q/Q	12.52%	Earnings	Nov 08 BMO	Avg Volume	261.27K	Price	58.46
SMA20	6.39%	SMA50	3.26%	SMA200	-3.72%	Trades		Volume	302,520	Change	1.67%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Initiated	Leerink Partners	Outperform	$80
Oct-11-24	Initiated	Piper Sandler	Overweight	$68
Mar-15-24	Initiated	CapitalOne	Overweight	$80
Aug-22-23	Reiterated	H.C. Wainwright	Buy	$60 → $73
Mar-01-23	Initiated	Guggenheim	Buy	$55
Sep-07-22	Initiated	H.C. Wainwright	Buy	$50
Nov-02-21	Initiated	Truist	Buy	$70
May-07-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-19	Initiated	Guggenheim	Buy
May-10-19	Downgrade	Raymond James	Strong Buy → Outperform	$73 → $82
Oct-16-17	Reiterated	Canaccord Genuity	Buy	$60 → $66
Jul-31-17	Initiated	Canaccord Genuity	Buy	$60
Feb-22-17	Downgrade	ROTH Capital	Buy → Neutral
Jun-23-16	Initiated	Raymond James	Strong Buy	$68
May-24-16	Downgrade	Standpoint Research	Buy → Hold
Nov-13-15	Initiated	Standpoint Research	Buy	$54
Sep-28-15	Upgrade	ROTH Capital	Neutral → Buy	$67 → $60
Aug-05-15	Reiterated	Oppenheimer	Outperform	$74 → $65
Aug-04-15	Reiterated	ROTH Capital	Neutral	$70 → $67
Jul-31-15	Reiterated	Oppenheimer	Outperform	$72 → $74

Show Previous Ratings

Jan-15-25 09:40AM	Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? (Zacks)
Jan-13-25 11:12AM	Alcami Announces CEO Transition (PR Newswire)
06:50AM	ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook (GlobeNewswire)
Jan-02-25 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity (GlobeNewswire)
Jan-01-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
04:05PM	Loading…
Dec-30-24 04:05PM	ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 12:00PM	All You Need to Know About ANI (ANIP) Rating Upgrade to Buy (Zacks)
Dec-18-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Dec-02-24 02:21PM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Nov-26-24 04:30PM	ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
09:55AM	Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect? (Zacks)
Nov-20-24 12:00PM	ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Nov-14-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
Nov-09-24 04:00AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-08-24 10:00AM	Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics (Zacks) +5.24%
08:21AM	Loading…
08:21AM	ANI Pharma Boosts FY24 Outlook As Q3 Results Top Estimates - Update (RTT News)
08:05AM	ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates (Zacks)
06:58AM	ANI: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Nov-07-24 07:06AM	ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-04-24 04:30PM	ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November (GlobeNewswire)
Nov-01-24 10:00AM	Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline (Zacks)
Oct-30-24 05:00PM	ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET (GlobeNewswire)
Oct-25-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% (GlobeNewswire)
Oct-24-24 06:50AM	ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-23-24 09:20AM	ANI Pharmaceuticals price target raised to $62 from $60 at Truist (TipRanks)
Oct-21-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Oct-15-24 12:10PM	Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-11-24 01:40PM	ANI Pharmaceuticals Shifts Focus From Generics To High-Margin Brand Assets, Analyst Sees Strong Potential (Benzinga)
Oct-09-24 09:55AM	Wall Street Analysts Predict a 42.98% Upside in ANI (ANIP): Here's What You Should Know (Zacks)
09:40AM	Loading…
Sep-27-24 09:40AM	Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? (Zacks)
Sep-26-24 06:50AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Ketoconazole Shampoo, 2% (GlobeNewswire)
Sep-16-24 08:53AM	ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences (GlobeNewswire)
06:50AM	ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences (GlobeNewswire)
Sep-13-24 06:50AM	ANI Pharmaceuticals Launches Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution (GlobeNewswire)
Sep-11-24 06:50AM	ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger (Business Wire)
Sep-10-24 02:09PM	ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences (GlobeNewswire) -5.13%
09:00AM	Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement (Business Wire)
Aug-28-24 12:15PM	ANI Pharmaceuticals, Inc. (ANIP): A Cheap Pharmaceutical Stock to Buy According to Short Sellers (Insider Monkey)
Aug-15-24 09:40AM	Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? (Zacks)
Aug-13-24 04:05PM	ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers' Option to Purchase Additional Notes (GlobeNewswire)
Aug-07-24 09:44PM	ANI Pharmaceuticals, Inc. Prices Upsized $275.0 Million Convertible Senior Notes Offering (GlobeNewswire) -9.92%
07:00AM	ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering (GlobeNewswire)
Aug-06-24 10:00AM	Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics (Zacks) +6.98%
08:05AM	ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:58AM	ANI: Q2 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance (GlobeNewswire)
Aug-05-24 09:16AM	Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-31-24 07:00AM	ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET (GlobeNewswire)
Jul-15-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of L-Glutamine Oral Powder (GlobeNewswire)
Jul-02-24 07:00AM	ANI Pharmaceuticals Announces the FDA Approval and Launch of Naproxen Delayed-Release Tablets, USP (GlobeNewswire)
Jun-25-24 07:00AM	ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year 2024 New Jersey Award Winner (GlobeNewswire)
Jun-24-24 11:28AM	Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal (Benzinga) +7.33%
11:14AM	Alimera Sciences shares jump by 77% after being acquired by ANI (Pharmaceutical Technology)
06:50AM	ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences (GlobeNewswire)
Jun-13-24 08:53AM	Implied Volatility Surging for ANI Pharmaceuticals (ANIP) Stock Options (Zacks)
Jun-06-24 01:00PM	Insider Sale: SVP & CFO Stephen Carey Sells 5,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-29-24 04:30PM	ANI Pharmaceuticals to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-20-24 10:52AM	ANI Pharmaceuticals Launches Kionex Suspension (MT Newswires)
09:35AM	Down -6.19% in 4 Weeks, Here's Why ANI (ANIP) Looks Ripe for a Turnaround (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Kionex Suspension (GlobeNewswire)
May-18-24 02:33AM	Director Renee Tannenbaum Sells 2,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
May-16-24 07:00PM	Insider Selling: President & CEO Nikhil Lalwani Sells Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
05:08PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,101,821, According to a Recent SEC Filing (MT Newswires)
May-13-24 03:03AM	ANI Pharmaceuticals Inc (ANIP) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ... (GuruFocus.com)
May-11-24 10:16AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 01:48PM	ANI Pharmaceuticals Reports Strong Q1 2024 Results, Surpassing Revenue Expectations (GuruFocus.com)
11:54AM	ANIP Stock Earnings: ANI Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	ANI (ANIP) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:26AM	ANI Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; Reaffirms Full Year 2024 Earnings, Revenue Guidance (MT Newswires)
06:58AM	ANI: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	ANI Pharmaceuticals Reports Record First Quarter 2024 Financial Results and Reiterates 2024 Guidance (GlobeNewswire)
May-09-24 08:46AM	Why Earnings Season Could Be Great for ANI Pharmaceuticals (ANIP) (Zacks)
May-06-24 11:26AM	ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store? (Zacks)
May-03-24 05:51PM	Ani Pharmaceuticals Insider Sold Shares Worth $1,332,400, According to a Recent SEC Filing (MT Newswires)
10:00AM	ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
May-01-24 04:30PM	ANI Pharmaceuticals to Participate at Two Upcoming Healthcare Conferences (GlobeNewswire)
Apr-18-24 04:05PM	ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET (GlobeNewswire)
Apr-15-24 12:10PM	Why ANI (ANIP) is Poised to Beat Earnings Estimates Again (Zacks)
Apr-10-24 06:15PM	ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know (Zacks)
Apr-09-24 06:50AM	ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension (GlobeNewswire)
Apr-05-24 09:30AM	Wall Street Analysts Think ANI (ANIP) Is a Good Investment: Is It? (Zacks)
Apr-04-24 06:50AM	ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis (GlobeNewswire)
Apr-03-24 06:50AM	ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium (GlobeNewswire)
Apr-02-24 06:15PM	ANI Pharmaceuticals (ANIP) Dips More Than Broader Market: What You Should Know (Zacks)
Mar-27-24 06:15PM	ANI Pharmaceuticals (ANIP) Rises Yet Lags Behind Market: Some Facts Worth Knowing (Zacks)
06:50AM	ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP (GlobeNewswire)
Mar-26-24 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run? (Zacks)
Mar-22-24 09:54PM	NYCB, Vista Outdoor, Cardlytics, and More Stocks See Action From Activist Investors (Barrons.com)
Mar-21-24 06:00PM	ANI Pharmaceuticals (ANIP) Outpaces Stock Market Gains: What You Should Know (Zacks)
Mar-20-24 09:30AM	ANI (ANIP) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-19-24 06:15PM	ANI Pharmaceuticals (ANIP) Gains But Lags Market: What You Should Know (Zacks)
Mar-14-24 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-08-24 11:54PM	ANI Pharmaceuticals Inc CEO Nikhil Lalwani Sells 45,257 Shares (GuruFocus.com)
Mar-06-24 11:29PM	Director Antonio Pera Sells 7,000 Shares of ANI Pharmaceuticals Inc (ANIP) (GuruFocus.com)
12:00PM	What Makes ANI Pharmaceuticals (ANIP) a Strong Momentum Stock: Buy Now? (Zacks)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 09:30AM	Wall Street Analysts See ANI (ANIP) as a Buy: Should You Invest? (Zacks)
09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
08:35AM	ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2023 Earnings Call Transcript (Insider Monkey)

ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. It operates through the Generics, Established Brands, and Other, and Rare Disease segments. The Generics, Established Brands, and Other segment consists of contract manufactured products, development services, royalties, and other. The Rare Disease segment involves the operations related to Cortrophin Gel. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jan 13 '25	Sale	53.92	400	21,568	55,588	Jan 13 04:15 PM
CAREY STEPHEN P.	SVP & CFO	Dec 17 '24	Sale	55.79	7,500	418,425	154,468	Dec 18 05:59 PM
CAREY STEPHEN P.	Officer	Dec 17 '24	Proposed Sale	55.25	7,500	414,375		Dec 17 05:35 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Dec 13 '24	Sale	56.24	250	14,060	55,988	Dec 16 04:20 PM
Davis Krista	SVP, CHIEF HR OFFICER	Dec 11 '24	Sale	60.00	1,000	60,000	49,059	Dec 12 05:08 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Option Exercise	29.00	30,000	870,000	403,859	Nov 27 05:38 PM
Lalwani Nikhil	PRESIDENT & CEO	Nov 26 '24	Sale	57.99	33,481	1,941,442	370,378	Nov 27 05:38 PM
Lalwani Nikhil	Officer	Nov 26 '24	Proposed Sale	57.99	33,481	1,941,484		Nov 26 07:44 PM
Mutz Christopher	HEAD OF RARE DISEASE	Nov 15 '24	Sale	57.70	6,500	375,050	76,777	Nov 18 04:03 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Nov 13 '24	Sale	61.36	250	15,340	56,238	Nov 14 04:16 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Oct 14 '24	Sale	57.19	250	14,298	56,488	Oct 15 05:57 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 13 '24	Sale	56.82	250	14,205	56,738	Sep 16 04:50 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '24	Sale	59.62	250	14,905	56,988	Aug 14 08:29 AM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 18 '24	Sale	62.00	2,743	170,066	632,620	Jul 19 05:30 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 16 '24	Sale	64.27	22,000	1,413,940	649,620	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 17 '24	Sale	63.16	14,257	900,472	635,363	Jul 17 07:07 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jul 15 '24	Sale	63.38	11,000	697,180	671,620	Jul 17 07:07 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 12 '24	Sale	64.91	250	16,228	58,981	Jul 15 04:38 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jul 01 '24	Sale	63.44	20,000	1,268,800	193,226	Jul 02 08:58 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 21 '24	Sale	58.90	20,000	1,178,000	682,620	Jun 24 04:12 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 20 '24	Sale	59.86	11,447	685,217	702,620	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 18 '24	Sale	60.76	10,607	644,481	714,067	Jun 20 07:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jun 17 '24	Sale	61.41	7,946	487,964	724,674	Jun 20 07:11 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 13 '24	Sale	63.80	250	15,950	59,231	Jun 14 05:23 PM
Marken James G.	SVP OPS & PROD DEV	Jun 07 '24	Option Exercise	52.70	12,550	661,366	128,916	Jun 11 04:51 PM
Gutwerg Ori	SVP, GENERICS	Jun 05 '24	Sale	67.00	2,985	199,995	77,227	Jun 06 06:21 PM
CAREY STEPHEN P.	SVP & CFO	Jun 04 '24	Sale	63.58	5,000	317,900	161,968	Jun 06 07:34 AM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Jun 03 '24	Sale	64.41	20,000	1,288,200	213,226	Jun 04 06:08 PM
Mutz Christopher	HEAD OF RARE DISEASE	May 21 '24	Sale	61.61	2,000	123,220	83,277	May 22 06:14 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 20 '24	Sale	61.81	12,855	794,568	732,620	May 21 05:21 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 16 '24	Sale	63.84	16,459	1,050,743	751,311	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 15 '24	Sale	65.86	14,850	978,021	767,770	May 17 06:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	May 17 '24	Sale	62.09	5,836	362,357	745,475	May 17 06:05 PM
TANNENBAUM RENEE P	Director	May 16 '24	Sale	63.87	2,000	127,740	18,211	May 17 06:01 PM
Lalwani Nikhil	PRESIDENT & CEO	May 14 '24	Sale	66.10	16,669	1,101,821	377,505	May 16 05:02 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	May 13 '24	Sale	67.69	250	16,922	59,481	May 13 05:25 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	May 01 '24	Sale	66.62	20,000	1,332,400	233,226	May 03 05:48 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 19 '24	Sale	65.17	16,809	1,095,443	782,620	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 18 '24	Sale	64.98	10,423	677,287	799,429	Apr 22 06:26 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 17 '24	Sale	65.40	9,520	622,608	809,852	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 15 '24	Sale	66.33	7,414	491,771	825,206	Apr 17 04:33 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Apr 16 '24	Sale	66.20	5,834	386,211	819,372	Apr 17 04:33 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Apr 12 '24	Sale	67.79	250	16,948	59,731	Apr 15 06:28 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Apr 01 '24	Sale	67.25	20,000	1,345,000	253,226	Apr 02 06:59 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Mar 13 '24	Sale	66.54	250	16,635	59,981	Mar 13 04:48 PM
Gassert Chad	SVP - CORP. DEV. & STRATEGY	Mar 11 '24	Sale	65.81	20,000	1,316,200	273,226	Mar 13 04:44 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 08 '24	Sale	67.17	10,000	671,700	832,620	Mar 11 06:43 PM
CAREY STEPHEN P.	SVP & CFO	Mar 11 '24	Sale	65.55	7,787	510,438	177,712	Mar 11 06:39 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 06 '24	Sale	65.52	28,965	1,897,787	444,981	Mar 08 07:25 PM
Lalwani Nikhil	PRESIDENT & CEO	Mar 08 '24	Sale	67.13	16,292	1,093,682	411,629	Mar 08 07:25 PM
Marken James G.	SVP OPS & PROD DEV	Mar 07 '24	Sale	66.37	24,338	1,615,313	124,492	Mar 07 09:42 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 07 '24	Sale	66.35	15,085	1,000,890	842,620	Mar 07 09:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 06 '24	Sale	65.47	14,822	970,396	857,705	Mar 07 09:11 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Mar 05 '24	Sale	65.35	10,093	659,578	872,527	Mar 07 09:11 PM
Mutz Christopher	HEAD OF RARE DISEASE	Mar 05 '24	Sale	66.00	5,000	330,000	87,387	Mar 06 04:24 PM
Pera Antonio R	Director	Mar 04 '24	Sale	65.20	7,000	456,400	26,627	Mar 06 04:20 PM
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Feb 13 '24	Sale	56.04	250	14,010	36,799	Feb 13 08:05 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 23 '24	Sale	56.44	15,000	846,600	882,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 22 '24	Sale	55.95	5,692	318,467	897,620	Jan 23 05:32 PM
Shanmugam Muthusamy	HEAD OF R&D, COO-NOVITIUM OPS	Jan 19 '24	Sale	55.57	4,524	251,399	903,312	Jan 23 05:32 PM

CRDF

Cardiff Oncology Inc

ANIP

ANI Pharmaceuticals Inc

Upgrade your FINVIZ experience